Clinical Trials Logo
  1. Home
  2. Anosmia
  3. NCT04951362

Role of Ivermectin Nanosuspension as Nasal Spray in Treatment of Persistant Post covid19 Anosmia

Anosmia Clinical Trial

Official title:
Studying the Expected Effect of Ivermectin Nanosuspension as Nasal Spray Upon Post covid19 Persistant Anosmia

Clinical Trial Summary

ivermectin is FDA approaved antiparasitic drug which is also claimed to be having potent in vitro antiviral effect,so we are tryying to study itsovid19 anosmia effect upon releiving post covid19 anosmia

Clinical Trial Description

ivermectin is FDA approaved antiparasitic drug which is also claimed to be having potent in vitro antiviral effect,so we are tryying to study itsovid19 anosmia effect upon releiving post covid19 anosmia as one of the most characteresic symptoms of covid19 infection ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04951362
Study type Interventional
Source South Valley University
Contact Zaky Aref, MD
Phone +201001771210
Email doctor.aref@hotmail.com
Status Recruiting
Phase Phase 2/Phase 3
Start date April 20, 2021
Completion date May 15, 2022
View Details
See also
  Status Clinical Trial Phase
Terminated NCT04964414 - Treatment of Pediatric Patients That Lost Sense of Smell Due to COVID-19 Phase 1/Phase 2
Completed NCT05812209 - Stellate Ganglion Block to Treat Long COVID 19 Case Series
Completed NCT05445921 - Stellate Ganglion Block for COVID-19-Induced Olfactory Dysfunction Phase 1/Phase 2
Withdrawn NCT02179554 - Does Cardiopulmonary Bypass Change Olfaction?
Completed NCT04957563 - Clinical Utility of Olfactory Rehabilitation: Treatment for Pacients With Neurosensorial Anosmia N/A
Terminated NCT03680911 - NAC for Head Trauma-induced Anosmia Phase 3
Completed NCT04657809 - Clinical Assessment of Insulin Fast Dissolving Film in Treatment of Post Infection Anosmia Phase 2
Completed NCT04853836 - Olfactory Disfunction and Co-ultraPEALut Phase 4
Recruiting NCT05040659 - Longitudinal At Home Smell Testing to Detect Infection by SARS-CoV-2
Recruiting NCT05562050 - Characteristics of the Anosmic Olfactory Mucosa
Completed NCT05152030 - The Clinical Applicability of the 'TIB' Olfactory Test Device
Recruiting NCT05384561 - Olfactory Training as a Treatment for Olfactory Dysfunction Post COVID-19 N/A
Enrolling by invitation NCT04764981 - Olfactory Training for Olfactory Dysfunction After Coronavirus Disease - 19 (COVID-19) N/A
Withdrawn NCT04408391 - Brain MRI Imaging in Patients With SARS-Cov2 (COVID-19) Infection With or Without Anosmia
Completed NCT04361474 - Trial Evaluating the Efficacy of Local Budesonide Therapy in the Management of Hyposmia in COVID-19 Patients Without Signs of Severity Phase 3
Completed NCT03990766 - Smell Changes & Efficacy of Nasal Theophylline Phase 2
Completed NCT04797936 - BNO 1030 Extract (Imupret) in the Treatment of Mild Forms of COVID-19 Phase 4
Recruiting NCT04528329 - Anosmia and / or Ageusia and Early Corticosteroid Use Phase 4
Completed NCT04789499 - Smell in Covid-19 and Efficacy of Nasal Theophylline Phase 2
Recruiting NCT04384042 - Malaysian COVID-19 Anosmia Study (Phase 2) - A Nationwide Multicentre Case-Control Study